dc.contributor.author | Montuori, Nunzia | |
dc.contributor.author | Pesapane, Ada | |
dc.contributor.author | Rossi, Francesca Wanda | |
dc.contributor.author | Giudice, Valentina | |
dc.contributor.author | De Paulis, Amato | |
dc.contributor.author | Selleri, Carmine | |
dc.contributor.author | Ragno, Pia | |
dc.date.accessioned | 2020-05-22T12:56:54Z | |
dc.date.available | 2020-05-22T12:56:54Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Montuori N, Pesapane A, Rossi FW, Giudice V, De Paulis A, Selleri C, Ragno P. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer. Translational Medicine @ UniSa 2016, 15(3): 15-21. | it_IT |
dc.identifier.issn | 2239-9747 | it_IT |
dc.identifier.uri | http://www.translationalmedicine.unisa.it/index | it_IT |
dc.identifier.uri | http://elea.unisa.it:8080/xmlui/handle/10556/4481 | |
dc.identifier.uri | http://dx.doi.org/10.14273/unisa-2679 | |
dc.description.abstract | The urokinase (uPA)-type
plasminogen activator receptor (uPAR) is a GPIanchored receptor that focuses urokinase (uPA)
proteolytic activity on the cell surface. uPAR also
regulates cell adhesion, migration and proliferation,
protects from apoptosis and contributes to epithelial
mesenchymal transition (EMT), independently of
uPA enzymatic activity. Indeed, uPAR interacts with
beta1, beta2 and beta3 integrins, thus regulating their
activities. uPAR cross-talks with receptor tyrosine
kinases through integrins and regulates cancer cell
dormancy, proliferation and angiogenesis. Moreover,
uPAR mediates uPA-dependent cell migration and
chemotaxis induced by fMet-Leu-Phe (fMLF),
through its association with fMLF-receptors (fMLFRs). Further, uPAR is an adhesion receptor because
it binds vitronectin (VN), a component of provisional
extracellular matrix. High uPAR expression predicts
for more aggressive disease in several cancer types
for its ability to increase invasion and metastasis. In
fact, uPAR has been hypothesized to be the link
between tumor cell dormancy and proliferation that
usually precedes the onset of metastasis. Thus,
inhibiting uPAR could be a feasible approach to
affect tumor growth and metastasis.
Here, we review the more recent advances in the
development of uPAR-targeted anti-cancer
therapeutic agents suitable for further optimization or
ready for the evaluation in early clinical trials. | it_IT |
dc.format.extent | P. 15-21 | it_IT |
dc.language.iso | en | it_IT |
dc.source | UniSa. Sistema Bibliotecario di Ateneo | it_IT |
dc.subject | uPAR | it_IT |
dc.subject | Metastasis | it_IT |
dc.subject | Plasminogen activation | it_IT |
dc.subject | Monoclonal antibody | it_IT |
dc.subject | Small molecules | it_IT |
dc.title | Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer | it_IT |
dc.type | Article | it_IT |